Alzheimers Disease & Dementia

About us

The 20th International Conference on Alzheimer’s Disease & Dementia, scheduled for July 20–21, 2026 in Amsterdam, Netherlands, brings together global leaders committed to advancing the science, diagnosis, and treatment of neurodegenerative disorders. Guided by the theme “Neurorestorative Dementia Science: Precision Biomarkers, Brain-Repair Pathways & AI-Enabled Cognitive Care,” this landmark event unites neurologists, geriatric specialists, neuroscientists, psychologists, geneticists, radiologists, pharmacologists, technologists, and healthcare professionals working at the forefront of dementia research and clinical innovation. The conference provides a dynamic platform to explore emerging breakthroughs in early detection, neuroprotective strategies, disease-modifying therapeutics, and digital cognitive technologies. Participants will engage in high-impact keynote sessions, interactive panel discussions, hands-on workshops, young researcher forums, poster presentations, and translational research dialogues. Emphasis will be placed on precision biomarkers, regenerative brain repair pathways, synaptic restoration, AI-driven diagnostic frameworks, neuroimaging advancements, caregiver burden solutions, and holistic dementia care models. The congress also highlights novel trials in amyloid and tau-targeting therapies, lifestyle interventions, personalized rehabilitation, and community health strategies supporting aging populations. By fostering global collaboration and cross-disciplinary knowledge exchange, the conference aims to accelerate meaningful progress toward effective prevention, improved patient outcomes, enhanced quality of life, and ultimately, a world free from dementia. Join us in Amsterdam to be part of a transformative scientific journey shaping the future of Alzheimer’s and dementia care worldwide.

Sessions

Neurorestorative Pathways & Synaptic Repair Mechanisms

Exploration of neurorestorative pathways focuses on how the brain repairs synaptic structures damaged during Alzheimer’s progression. Research highlights mechanisms such as neurotrophic signaling, synaptic plasticity modulation, and mitochondrial stabilization to restore neuronal communication. Scientists are now decoding molecular repair signatures that guide axonal regrowth, dendritic spine regeneration, and enhanced neurotransmission efficiency. Emerging therapeutics include synaptic modulators, growth-factor mimetics, and neurorestoration-inducing peptides capable of reversing early structural damage. Preclinical models demonstrate improved memory circuits by enhancing long-term potentiation and rebuilding disrupted neural networks. Combining bioengineering, stem-cell–derived exosomes, and pharmacologic boosters is offering new avenues to promote robust synaptic recovery. Understanding how neurodegeneration disrupts these mechanisms enables the creation of targeted interventions that strengthen resilience in vulnerable regions such as the hippocampus and cortex. Neurorestorative science provides a foundation for disease-modifying treatments aimed not only at slowing decline but also improving functional cognition, independence, and long-term brain health in individuals affected by Alzheimer’s disease.

Precision Biomarkers, Early Detection & Predictive Neuroanalytics

Precision biomarker research is transforming the ability to detect Alzheimer’s disease years before symptoms arise. Advanced blood-based markers, CSF signatures, polygenic risk scores, and digital biomarkers offer highly sensitive indicators of early pathology. Predictive neuroanalytics leverages AI algorithms to track subtle cognitive fluctuations, speech patterns, retinal changes, and gait abnormalities, enabling a more accurate forecast of progression. Novel biomarkers, including phosphorylated tau isoforms, neurofilament light chain, and synaptic proteins, provide comprehensive mapping of neuronal injury and misfolding processes. Imaging biomarkers such as amyloid-PET, tau-PET, and volumetric MRI are increasingly used to quantify disease burden and predict trajectory. The integration of multi-omics approaches—genomics, proteomics, metabolomics—supports personalized disease-risk profiling. These innovations empower clinicians to intervene earlier, refine therapeutic planning, and stratify patients for clinical trials with greater accuracy. As precision diagnostics evolve, they offer new possibilities for monitoring treatment response, developing targeted therapies, and fundamentally reshaping the landscape of Alzheimer’s prevention and early detection.

AI-Enabled Cognitive Monitoring & Digital Dementia Diagnostics

Artificial intelligence is reshaping dementia diagnostics by enabling continuous, real-time monitoring of cognitive health. AI-driven tools analyze speech, behavior, writing patterns, navigation habits, and digital device interaction to detect early cognitive impairment long before traditional assessments. Machine learning algorithms can identify micro-patterns in memory lapses, reaction times, decision-making, and emotional signals, providing highly accurate and dynamic cognitive profiling. Digital platforms, smartphone-based screening, and wearable sensors generate objective, high-frequency data streams that support remote diagnosis and longitudinal tracking. AI-powered risk scoring systems integrate medical history, imaging data, and biomarker profiles to create personalized disease trajectories. These innovations improve accessibility to diagnostic care, especially for patients in remote or underserved regions. Digital intelligence enhances clinical decision-making, supports timely intervention, and improves adherence to therapeutic plans. As AI models grow more interpretable and clinically validated, they offer powerful support for clinicians and caregivers, optimizing early detection, treatment adjustment, and patient engagement throughout the continuum of dementia care.

Molecular Neurodegeneration & Protein Misfolding Dynamics

The study of molecular neurodegeneration examines how misfolded proteins such as amyloid-β and tau disrupt neuronal integrity and accelerate Alzheimer’s pathology. Misfolding, aggregation, and propagation across neural circuits trigger synaptic loss, mitochondrial dysfunction, oxidative stress, and inflammatory cascades. Research focuses on identifying the earliest molecular triggers of plaque formation, tau hyperphosphorylation, and neurofibrillary tangle spread. Advanced structural biology, cryo-EM imaging, and molecular modeling are providing unprecedented insights into protein conformational changes and toxic oligomer formation. Therapeutic strategies are increasingly targeting protein clearance mechanisms, including autophagy enhancement, proteasome activation, and chaperone-mediated stabilization. Interrupting aggregation pathways may halt or reverse neuronal injury. Understanding misfolding kinetics and transmission mechanisms supports development of next-generation therapies capable of slowing progression and preserving cognitive function. Molecular insights remain foundational for creating disease-modifying treatments that directly address the root biology of Alzheimer’s disease.

Genomic & Epigenomic Drivers of Alzheimer’s Progression

Genomic and epigenomic research is uncovering the underlying factors that shape Alzheimer’s susceptibility, onset, and progression. Key genetic contributors, including APOE variants, TREM2 mutations, and polygenic risk factors, help explain individual differences in disease vulnerability. Epigenomic changes—such as DNA methylation, histone modification, and chromatin remodeling—alter gene expression patterns linked to inflammation, synaptic health, and metabolic dysfunction. Environmental influences including stress, lifestyle, and toxin exposure can further modify epigenetic signatures, accelerating neurodegenerative processes. Advances in single-cell sequencing and spatial transcriptomics reveal cell-specific regulatory changes occurring in neurons, astrocytes, and microglia during disease evolution. Understanding these mechanisms enables precision profiling and supports development of targeted therapies that modulate gene expression pathways. Gene-editing tools, epigenetic modulators, and personalized risk assessment models hold promise for predicting progression and designing individualized treatment strategies rooted in genetic and regulatory biology.

Neuroinflammation, Microglial Function & Immune Modulation

Neuroinflammation plays a central role in Alzheimer’s disease, with microglia acting as key regulators of immune responses in the brain. Dysfunctional microglial activation contributes to synaptic loss, amyloid accumulation, and accelerated neurodegeneration. Research is advancing understanding of how cytokine signaling, inflammasome activity, and immune-mediated oxidative stress shape disease progression. Modulating microglial phenotypes shifting them from pro-inflammatory to neuroprotective states offers promising therapeutic potential. Novel drugs, monoclonal antibodies, and small molecules are being developed to regulate immune signaling pathways and restore balanced neuroimmune responses. Neuroinflammation biomarkers are increasingly used to stratify patients and guide personalized therapy decisions. Integrating immune modulation with other therapeutic strategies enhances the potential to slow cognitive decline and protect structural brain integrity.

Next-Generation Therapeutics: Anti-Amyloid & Anti-Tau Innovations

Next-generation therapeutics targeting amyloid and tau are reshaping the landscape of Alzheimer’s treatment. New anti-amyloid antibodies, tau aggregation inhibitors, small-molecule stabilizers, and dual-pathway modulators aim to reduce neurotoxic buildup and preserve neural networks. These therapies combine improved safety profiles with precision dosing and biomarker-guided monitoring. Advances in drug delivery systems increase blood–brain barrier penetration, maximizing therapeutic impact. Combination therapies that simultaneously target amyloid, tau, and inflammatory pathways show promise in modifying disease trajectories. Continuous clinical research is refining efficacy, identifying ideal treatment windows, and enabling earlier intervention. These innovations signal a major shift toward disease-modifying approaches capable of addressing core pathology.

Brain Connectomics, Network Disruption & Cognitive Mapping

Brain connectomics investigates how Alzheimer’s disrupts communication across neural networks. Advanced imaging reveals alterations in structural and functional connectivity within memory, attention, and executive processing circuits. Researchers map how signal transmission deteriorates as synapses fail, white-matter tracts degrade, and long-range communication becomes inefficient. Computational models simulate network breakdown and identify key nodes most vulnerable to early damage. These insights guide development of targeted therapies that restore connectivity through neurostimulation, behavioral training, and pharmacologic enhancement. Connectomic mapping provides precise biomarkers for progression, enabling personalized monitoring and intervention strategies.

Lifestyle, Nutrition & Neuroprotective Aging Strategies

Lifestyle and nutritional interventions play growing roles in delaying Alzheimer’s onset and promoting neuroprotective aging. Diet patterns such as MIND, Mediterranean, and ketogenic diets influence brain metabolism, inflammation, and oxidative balance. Physical activity enhances synaptic plasticity, improves vascular health, and increases neurotrophic factor expression. Sleep optimization, stress management, cognitive training, and social engagement support long-term brain resilience. Integrating lifestyle science with personalized risk profiles empowers individuals to adopt evidence-based prevention strategies.

Vascular Contributions to Cognitive Impairment & Aging

Vascular dysfunction significantly contributes to cognitive impairment, interacting with amyloid and tau pathology to accelerate decline. Reduced cerebral perfusion, microvascular injury, and endothelial dysfunction damage neurons and impair metabolic efficiency. Research explores therapeutic approaches including vascular-targeted drugs, antihypertensives, antithrombotics, and lifestyle interventions that improve cerebrovascular integrity. Identifying early vascular biomarkers supports intervention long before cognitive symptoms emerge.

Neuroimaging Advances: MRI, PET & Multimodal Brain Analytics

Modern neuroimaging tools provide unmatched visibility into Alzheimer’s progression. High-resolution MRI quantifies structural atrophy, while PET imaging maps amyloid, tau, and neuroinflammation. Multimodal approaches integrate metabolic, functional, and molecular imaging for comprehensive brain analysis. AI-enhanced imaging improves diagnostic accuracy, disease staging, and treatment-response assessment.

Digital Therapeutics, VR-Based Cognitive Rehabilitation & Remote Care

Digital therapeutics are transforming dementia rehabilitation through interactive training, VR-based exercises, and remote cognitive therapy. Personalized digital protocols stimulate memory circuits, support motor planning, and promote cognitive engagement. Remote care platforms increase accessibility, reduce caregiver burden, and enable consistent long-term monitoring.

Psychiatric Symptoms in Dementia: Behavior, Mood & Neuropsychology

Behavioral and psychiatric symptoms significantly affect Alzheimer’s outcomes. Understanding neural mechanisms behind agitation, anxiety, hallucinations, and mood disorders supports development of targeted interventions. Integrative care models combine medication, behavioral therapy, and environmental adjustments to improve quality of life.

Caregiver Support Models, Clinical Pathways & Dementia-Friendly Systems

Caregiver support is essential for managing long-term dementia care. Effective models emphasize education, emotional support, respite services, and decision-making tools. Dementia-friendly systems integrate community planning, specialized clinical pathways, and coordinated care frameworks to enhance patient and caregiver well-being.

Drug Discovery, Translational Neuroscience & Clinical Trial Innovations

Drug discovery in Alzheimer’s is accelerating through high-throughput screening, AI modeling, and human-relevant cellular systems. Translational neuroscience bridges laboratory findings with clinical testing, improving trial design and patient selection. Innovations aim to reduce failure rates, optimize dosing, and bring disease-modifying therapies to patients faster.

Market Analysis

The global market for Alzheimer’s disease and dementia research, diagnosis, and care is expanding rapidly as populations age, prevalence rises, and scientific innovation accelerates. Dementia currently affects tens of millions worldwide and represents one of the largest unmet medical and social care challenges; demand for better diagnostics, disease-modifying therapies, and care solutions is driving sustained investment from biopharma, medtech, payers, and public health systems. Key growth drivers include demographic trends (aging populations in developed and many developing regions), increasing disease awareness and screening, and an improving R&D environment. Advances in biomarker science (blood-based assays, PET tracers, CSF biomarkers), multi-omics, and neuroimaging are enabling earlier and more reliable diagnosis, which expands the addressable population for interventions and clinical trials. Simultaneously, regulatory pathways have evolved to accommodate biomarker-guided trial designs and conditional approvals for disease-modifying candidates, encouraging continued pipeline investment. Therapeutic innovation is a major market catalyst. Multiple modalities are being pursued: small molecules targeting amyloid, tau, and synaptic dysfunction; monoclonal and bispecific antibodies; gene and cell therapies; immune-modulatory approaches; and novel repurposed agents. The shift from symptomatic treatments toward potential disease-modifying therapies (DMTs) has amplified commercial interest—successful DMT approvals could dramatically increase market value by creating demand for companion diagnostics, early screening programs, and long-term treatment management services.

Digital health and care models are another fast-growing segment. AI-enabled diagnostic tools, remote cognitive monitoring, digital therapeutics, and telecare platforms improve early detection, longitudinal monitoring, and care coordination. These technologies also support decentralized clinical trials and remote patient engagement, reducing costs and accelerating recruitment. The caregiving and services market home care, memory clinics, long-term care facilities, and caregiver support services remains substantial and will grow as health systems adapt to provide integrated dementia pathways. Regionally, North America and Western Europe currently dominate investment, trial activity, and market uptake due to mature healthcare systems, public funding, and established reimbursement mechanisms. Asia-Pacific is the fastest-growing region in terms of unmet need and potential market expansion, driven by rapidly aging societies, increased health spending, and growing clinical research capacity. Emerging markets present both demand and access challenges affordability, infrastructure, and workforce capacity need addressing to convert clinical innovation into broad public health impact. However, significant barriers temper market potential. High R&D costs, lengthy and failure-prone clinical trials, and the biological complexity of Alzheimer’s disease create scientific and financial risk. Reimbursement uncertainty for novel diagnostics and incremental benefits, fragmented care systems, and persistent gaps in primary care capacity and specialist access impede adoption. Ethical, privacy, and equity considerations around early diagnosis (preclinical biomarker positive individuals) must be managed thoughtfully, as must the economic burden on payers and families. Opportunities are substantial: integrated care models combining early biomarker screening, DMTs, digital monitoring, and caregiver support; value-based contracting and outcomes-based reimbursement; public-private partnerships to de-risk late-stage development; and broader adoption of remote technologies to scale diagnosis and care. Companies that align therapeutic innovation with scalable diagnostics, pragmatic trial designs, and robust payer evidence will be best positioned to capture long-term value.

Past Conference Report

Dementia-2025

With the great success of Dementia 2025, Conference Series LLC Ltd is proud to announce the “19th International Conference on Alzheimers Disease & Dementia”, which is going to be held on July 07-08, 2025 at Zurich, Switzerland.We welcome each and everyone from everypart of the world to travel to the insanity gathering that is command amid July 07-08, 2025. The principle subject of our meeting is "Advancements and Challenges in the Fields of Dementia Research" that covers intensive form of essentially important sessions. This meeting flow regarding enhancements within the field of insanity and about the new treatment techniques that square measure contrived by researchers to treat completely different maladies in less hard-to-please approach. This meeting goes concerning as a best stage for participants to search out concerning this pattern in insanity innovative work.

Dementia-2025 gathering can target the foremost recent and energizing developments in each facet of insanity think about that offers a noteworthy open door for agents over the world to fulfil, organize, and see new logical advancements. The 2 days gathering incorporates symposiums and exceptional keynote sessions semiconductor diode by notable and eminent speakers WHO exceed expectations within the field of insanity This Worldwide insanity Meeting likewise energizes the dynamic support of young understudies, forthcoming specialists and growing researchers as we have a tendency to square measure facilitating Poster Award Competition and Young analysis Forum at the gathering setting, This Dementia-2025 Conference is tailored to fulfil the needs of both eminent professionals and those just starting out in their professions. Dementia 2023 will serve as a major introduction to latest results and research in the field of Dementia and Alzheimer’s. It's a fantastic opportunity for everyone to engage in international networking and interact with world-class specialists. This worldwide Alzheimer’s summit will unite researchers, scientists, academicians, caregivers, healthcare professionals and neurology experts from all around the globe to have discussion on the latest trends and innovations in the field of dementia and Alzheimer’s. The Dementia congress strives to improve the coordination and delivery of care for those suffering from neurocognitive and brain ageing problems whilst discussing practical ideas for improving neurological disorders patients' quality of life.